LLY vs RLMD · P/E 39, rev $22.97B vs $692.3M cap
Eli Lilly and Company (LLY) versus Relmada Therapeutics Inc (RLMD) — a side-by-side from cached financials, not a winner call.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Relmada Therapeutics Inc (RLMD) is a biotechnology company listed on NASDAQ.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
RLMD does not have a complete income-statement cache yet.
LLY currently screens at market cap $991.62B and trailing P/E 39.5. RLMD currently screens at market cap $692.3M.
Not investment advice. Open the LLY and RLMD stock pages for the full models.
Not investment advice.